IMMUNITYBIO, INC. Operating Cash Flow
IMMUNITYBIO, INC. (IBRX) reported Operating Cash Flow of -$141.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$66.49M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$75.36M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$70.38M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$68.91M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$304.94M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$391.24M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$366.76M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$337.51M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$66.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$141.85M 10-Q · filed 2026-08-04 | -$212.23M derived: sum of 3 quarters · filed 2026-08-04 | -$281.14M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$75.36M 10-Q · filed 2026-05-07 | -$145.74M derived: sum of 2 quarters · filed 2026-05-07 | -$214.64M derived: sum of 3 quarters · filed 2026-05-07 | -$294.39M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$70.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$139.28M derived: sum of 2 quarters · filed 2026-02-23 | -$219.03M derived: sum of 3 quarters · filed 2026-08-04 | -$304.94M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$68.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$148.65M derived: sum of 2 quarters · filed 2026-08-04 | -$234.56M 10-Q · filed 2025-11-05 | -$319.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$79.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$165.65M 10-Q · filed 2026-08-04 | -$250.79M derived: sum of 3 quarters · filed 2026-08-04 | -$349.56M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$85.91M 10-Q · filed 2026-05-07 | -$171.05M derived: sum of 2 quarters · filed 2026-05-07 | -$269.81M derived: sum of 3 quarters · filed 2026-05-07 | -$370.16M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$85.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$183.91M derived: sum of 2 quarters · filed 2026-02-23 | -$284.25M derived: sum of 3 quarters · filed 2026-02-23 | -$391.24M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | -$98.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$199.11M derived: sum of 2 quarters · filed 2025-11-05 | -$306.09M 10-Q · filed 2025-11-05 | -$421.36M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | -$100.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$207.33M 10-Q · filed 2025-08-05 | -$322.60M derived: sum of 3 quarters · filed 2026-02-23 | -$410.00M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | -$106.98M 10-Q · filed 2025-05-12 | -$222.25M derived: sum of 2 quarters · filed 2026-02-23 | -$309.66M derived: sum of 3 quarters · filed 2026-02-23 | -$389.43M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | -$115.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$202.67M derived: sum of 2 quarters · filed 2026-02-23 | -$282.45M derived: sum of 3 quarters · filed 2026-02-23 | -$366.76M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$87.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$167.18M derived: sum of 2 quarters · filed 2024-11-12 | -$251.49M 10-Q · filed 2024-11-12 | -$342.21M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$79.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$164.08M 10-Q · filed 2024-08-12 | -$254.81M derived: sum of 3 quarters · filed 2025-03-03 | -$335.41M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | -$84.31M 10-Q · filed 2024-05-09 | -$175.04M derived: sum of 2 quarters · filed 2025-03-03 | -$255.64M derived: sum of 3 quarters · filed 2025-03-03 | -$346.89M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | -$90.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$171.33M derived: sum of 2 quarters · filed 2025-03-03 | -$262.58M derived: sum of 3 quarters · filed 2025-03-03 | -$337.51M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$80.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$171.85M derived: sum of 2 quarters · filed 2023-11-09 | -$246.78M 10-Q · filed 2023-11-09 | -$318.42M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | -$91.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$166.18M 10-Q · filed 2023-08-08 | -$237.82M derived: sum of 3 quarters · filed 2024-03-19 | -$310.54M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | -$74.93M 10-Q · filed 2023-05-11 | -$146.57M derived: sum of 2 quarters · filed 2024-03-19 | -$219.28M derived: sum of 3 quarters · filed 2024-03-19 | -$288.88M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | -$71.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$144.35M derived: sum of 2 quarters · filed 2024-03-19 | -$213.95M derived: sum of 3 quarters · filed 2024-03-19 | -$274.42M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | -$72.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$142.31M derived: sum of 2 quarters · filed 2022-11-09 | -$202.78M 10-Q · filed 2022-11-09 | -$260.38M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | -$69.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$130.06M 10-Q · filed 2022-08-08 | -$187.67M derived: sum of 3 quarters · filed 2023-03-01 | -$224.66M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | -$60.47M 10-Q · filed 2022-05-10 | -$118.07M derived: sum of 2 quarters · filed 2023-03-01 | -$155.06M derived: sum of 3 quarters · filed 2023-03-01 | -$201.09M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$57.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$94.59M derived: sum of 2 quarters · filed 2023-03-01 | -$140.62M derived: sum of 3 quarters · filed 2023-03-01 | -$171.72M 10-K · filed 2023-03-01 | -$70.45M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | -$36.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$83.01M derived: sum of 2 quarters · filed 2021-11-12 | -$114.12M 10-Q · filed 2021-11-12 | -$47.40M 10-Q · filed 2020-11-09 | -$219.75M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | -$46.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$77.13M 10-Q · filed 2021-08-12 | -$29.12M 10-Q · filed 2020-08-07 | -$182.76M derived: sum of 3 quarters · filed 2022-03-01 | -$199.33M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | -$31.11M 10-Q · filed 2021-05-14 | -$12.60M 10-Q · filed 2020-05-11 | -$136.74M derived: sum of 2 quarters · filed 2022-03-01 | -$153.31M derived: sum of 3 quarters · filed 2022-03-01 | -$170.14M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$105.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$122.20M derived: sum of 2 quarters · filed 2022-03-01 | -$139.03M derived: sum of 3 quarters · filed 2022-03-01 | -$152.11M 10-K · filed 2022-03-01 | -$61.36M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | -$16.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$33.40M derived: sum of 2 quarters · filed 2020-11-09 | -$46.48M 10-Q · filed 2020-11-09 | -$60.51M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | -$16.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$29.91M 10-Q · filed 2020-08-07 | -$43.94M derived: sum of 3 quarters · filed 2021-03-04 | -$61.51M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | -$13.08M 10-Q · filed 2020-05-11 | -$27.11M derived: sum of 2 quarters · filed 2021-03-04 | -$44.68M derived: sum of 3 quarters · filed 2021-03-04 | -$60.95M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | -$14.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$31.60M derived: sum of 2 quarters · filed 2021-03-04 | -$47.87M derived: sum of 3 quarters · filed 2021-03-04 | -$63.38M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | -$17.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$33.84M derived: sum of 2 quarters · filed 2019-11-05 | -$49.35M 10-Q · filed 2019-11-05 | -$62.99M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-06-30 | -$16.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$31.78M 10-Q · filed 2019-08-06 | -$45.42M derived: sum of 3 quarters · filed 2020-03-25 | -$55.55M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-03-31 | -$15.51M 10-Q · filed 2019-05-08 | -$29.15M derived: sum of 2 quarters · filed 2020-03-25 | -$39.28M derived: sum of 3 quarters · filed 2020-03-25 | |||||
| 2017-12-31 | -$13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$23.77M derived: sum of 2 quarters · filed 2020-03-25 | -$48.78M 10-K · filed 2020-03-25 | |||||
| 2017-09-30 | -$10.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$35.14M 10-Q · filed 2018-11-07 | ||||||
| 2017-06-30 | -$25.01M 10-Q · filed 2018-08-06 | |||||||
| 2016-12-31 | -$38.59M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |